Tudor Investment Corp ET AL trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 94.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,929 shares of the medical equipment provider’s stock after selling 245,521 shares during the quarter. Tudor Investment Corp ET AL’s holdings in Zimmer Biomet Holdings were worth $1,917,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Enterprise Financial Services Corp raised its position in shares of Zimmer Biomet Holdings by 0.3% in the 2nd quarter. Enterprise Financial Services Corp now owns 2,646 shares of the medical equipment provider’s stock worth $340,000 after acquiring an additional 9 shares in the last quarter. Sandy Spring Bank lifted its stake in shares of Zimmer Biomet Holdings by 1.7% in the 1st quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after purchasing an additional 20 shares during the period. Cleararc Capital Inc. lifted its stake in shares of Zimmer Biomet Holdings by 0.5% in the 1st quarter. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider’s stock valued at $598,000 after purchasing an additional 25 shares during the period. Parkside Financial Bank & Trust lifted its stake in shares of Zimmer Biomet Holdings by 3.9% in the 2nd quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after purchasing an additional 33 shares during the period. Finally, CWA Asset Management Group LLC lifted its stake in shares of Zimmer Biomet Holdings by 1.8% in the 2nd quarter. CWA Asset Management Group LLC now owns 1,952 shares of the medical equipment provider’s stock valued at $251,000 after purchasing an additional 34 shares during the period. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded down 0.05% during trading on Monday, reaching $117.03. 74,150 shares of the company’s stock traded hands. The firm has a market cap of $23.66 billion, a price-to-earnings ratio of 33.33 and a beta of 1.19. Zimmer Biomet Holdings, Inc. has a one year low of $95.63 and a one year high of $133.49. The company has a 50 day moving average of $114.50 and a 200 day moving average of $120.75.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.10 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. During the same quarter last year, the business earned $2.02 EPS. The business’s revenue was up 1.1% on a year-over-year basis. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 annualized dividend and a yield of 0.82%. Zimmer Biomet Holdings’s payout ratio is presently 27.59%.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/tudor-investment-corp-et-al-cuts-holdings-in-zimmer-biomet-holdings-inc-zbh/1603244.html.

Several equities research analysts recently weighed in on ZBH shares. Royal Bank Of Canada reiterated an “outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. SunTrust Banks, Inc. reissued a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet Holdings in a research report on Monday. Wells Fargo & Company restated a “market weight” rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Jefferies Group LLC restated a “buy” rating and set a $148.00 target price on shares of Zimmer Biomet Holdings in a report on Friday, June 30th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $135.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 28th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $136.55.

In other news, VP Tony W. Collins sold 16,986 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.07% of the stock is currently owned by insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.